MX2009008230A - Epitopes de celulas t reguladoras, composiciones y usos para los mismos. - Google Patents

Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Info

Publication number
MX2009008230A
MX2009008230A MX2009008230A MX2009008230A MX2009008230A MX 2009008230 A MX2009008230 A MX 2009008230A MX 2009008230 A MX2009008230 A MX 2009008230A MX 2009008230 A MX2009008230 A MX 2009008230A MX 2009008230 A MX2009008230 A MX 2009008230A
Authority
MX
Mexico
Prior art keywords
regulatory
compositions
cell epitopes
epitopes
methods
Prior art date
Application number
MX2009008230A
Other languages
English (en)
Spanish (es)
Inventor
Groot Anne De
William Martin
Dan Rivera
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39674696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008230(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of MX2009008230A publication Critical patent/MX2009008230A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
MX2009008230A 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos. MX2009008230A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89834707P 2007-01-30 2007-01-30
PCT/US2008/001148 WO2008094538A2 (en) 2007-01-30 2008-01-29 Regulatory t cell epitopes, compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2009008230A true MX2009008230A (es) 2010-03-08

Family

ID=39674696

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2009008230A MX2009008230A (es) 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2015014429A MX347197B (es) 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2018015933A MX2018015933A (es) 2007-01-30 2009-07-30 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2015014429A MX347197B (es) 2007-01-30 2008-01-29 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2018015933A MX2018015933A (es) 2007-01-30 2009-07-30 Epitopes de celulas t reguladoras, composiciones y usos para los mismos.

Country Status (11)

Country Link
US (18) US7884184B2 (show.php)
EP (13) EP2450369A1 (show.php)
JP (10) JP4866467B2 (show.php)
KR (3) KR101722305B1 (show.php)
CN (4) CN101687912B (show.php)
AT (1) ATE525392T1 (show.php)
AU (1) AU2008211227B2 (show.php)
CA (6) CA3001783C (show.php)
IL (3) IL200129A (show.php)
MX (3) MX2009008230A (show.php)
WO (1) WO2008094538A2 (show.php)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE525392T1 (de) 2007-01-30 2011-10-15 Epivax Inc Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2622064B1 (en) 2010-10-01 2019-05-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2620070C2 (ru) * 2011-12-13 2017-05-22 Сантр Насьональ Де Ля Решерш Сьянтифик Модифицированные пептиды и их применение для лечения аутоиммунных заболеваний
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
NZ721105A (en) * 2013-12-06 2022-04-29 Broad Inst Inc Formulations for neoplasia vaccines
HUE057800T2 (hu) 2014-04-23 2022-06-28 Modernatx Inc Nukleinsav vakcinák
US10035823B2 (en) * 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
US20180179256A1 (en) * 2015-05-04 2018-06-28 Epivax, Inc. Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 Sequence
CN107921097A (zh) 2015-05-04 2018-04-17 埃皮瓦克斯公司 流感a/shanghai/2/2013 h7序列的改性h7血凝素糖蛋白
PL3377103T5 (pl) 2015-11-19 2025-07-07 Revitope Limited Komplementacja funkcjonalnego fragmentu przeciwciała dla dwuskładnikowego układu do przekierowanego zabijania niepożądanych komórek
PL238939B1 (pl) * 2016-11-02 2021-10-18 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu Peptyd immunosupresyjny i jego zastosowania
EP3691673A4 (en) 2017-10-05 2021-06-09 Epivax, Inc. REGULATORY T-LYMPHOCYTE EPITOPES
EP3622962A1 (en) * 2018-09-14 2020-03-18 advanceCOR GmbH Short cyclic peptides for the treatment of graves' disease
EP3963335B1 (en) * 2019-05-03 2024-08-21 Epivax Therapeutics, Inc. Neoantigens in cancer
KR20220160640A (ko) * 2020-03-27 2022-12-06 에피백스, 인크. 조절 t-세포 에피토프
JP2023519347A (ja) * 2020-03-27 2023-05-10 ビオテスト・アクチエンゲゼルシャフト 少なくとも１つの制御性ｔ細胞活性化エピトープを含むタンパク質
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
WO2022036193A2 (en) * 2020-08-13 2022-02-17 Epivax, Inc. Regulatory t cell epitopes
JP2023543801A (ja) * 2020-09-25 2023-10-18 エピバックス、インコーポレイテッド レトロインベルソ制御性ｔ細胞エピトープ
JP2024524730A (ja) * 2021-07-16 2024-07-05 デベヴェ・テクノロジーズ 対象におけるカシュー耐性を増大させるための免疫治療法
AU2024275787A1 (en) 2023-05-19 2025-11-27 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2556219B1 (fr) 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
JP3904238B2 (ja) 1996-03-20 2007-04-11 イムノメディクス， インコーポレイテッド グリコシル化されたヒト化ｂ細胞特異的抗体
DE69840723D1 (de) * 1997-02-11 2009-05-20 Immunomedics Inc Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
EP0981548A4 (en) * 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1180159B1 (en) 1999-05-28 2008-09-03 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders
US6445840B1 (en) 1999-05-28 2002-09-03 Omm, Inc. Micromachined optical switching devices
JP2003530847A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
AU2001278898A1 (en) 2000-07-10 2002-01-21 Xencor Method for disigning protein libraries with altered immunogenicity
CA2441095A1 (en) * 2001-03-15 2002-09-26 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified interferon beta with reduced immunogenicity
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MXPA04004417A (es) * 2001-11-12 2004-08-11 Merck Patent Gmbh Anticuerpo anti-tnf alfa modificado.
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
JP2005516607A (ja) 2002-02-07 2005-06-09 デルタ バイオテクノロジー リミテッド Ｈｉｖ阻害タンパク質
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1532262T3 (da) 2002-05-24 2013-09-16 Medtronic Inc Peptidamideringsfremgangsmåde
ATE472556T1 (de) * 2002-12-02 2010-07-15 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
CN1511958A (zh) * 2002-12-31 2004-07-14 王小宁 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20050042664A1 (en) * 2003-08-22 2005-02-24 Medimmune, Inc. Humanization of antibodies
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
EP2270045B8 (en) 2004-02-06 2015-02-25 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
KR101184391B1 (ko) 2004-02-09 2013-03-14 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
PL1737961T3 (pl) * 2004-03-19 2013-12-31 Merck Patent Gmbh Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania
ES2527292T3 (es) * 2004-03-31 2015-01-22 Genentech, Inc. Anticuerpos anti-TGF-beta humanizados
US7901688B2 (en) 2004-08-03 2011-03-08 Transtech Pharma, Inc. Rage fusion proteins
KR20070057818A (ko) 2004-08-03 2007-06-07 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질 및 이의 사용 방법
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
US7488804B2 (en) 2005-02-02 2009-02-10 The Regents Of The University Of California Modified fusion molecules for treatment of allergic disease
EP1844074B1 (en) 2005-02-03 2013-04-24 Antitope Limited Human antibodies and proteins
EA200800094A1 (ru) 2005-06-20 2008-06-30 Медарекс, Инк. Антитела cd19 и их использование
WO2007021494A2 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
CN100349921C (zh) * 2005-11-17 2007-11-21 中国人民解放军第四军医大学 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备
JP5096369B2 (ja) * 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
EA015992B1 (ru) * 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
GB0605735D0 (en) 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
AT503861B1 (de) † 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
ATE525392T1 (de) * 2007-01-30 2011-10-15 Epivax Inc Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
KR20100021627A (ko) 2007-06-08 2010-02-25 다우 글로벌 테크놀로지스 인크. Ｃｈ1 도메인의 절단에 의한 가용성 항체 단편의 발현

Also Published As

Publication number Publication date
KR20170037677A (ko) 2017-04-04
IL245478B (en) 2019-07-31
US20190030144A1 (en) 2019-01-31
EP2423221B1 (en) 2015-04-29
JP2021073255A (ja) 2021-05-13
CN112279911A (zh) 2021-01-29
JP2017165733A (ja) 2017-09-21
EP2125883B2 (en) 2020-11-18
US11045529B2 (en) 2021-06-29
HK1197250A1 (en) 2015-01-09
CN107011431A (zh) 2017-08-04
EP2423222A1 (en) 2012-02-29
IL200129A0 (en) 2010-04-15
CA3001783C (en) 2020-09-08
EP2423222B2 (en) 2020-07-29
US20180289787A1 (en) 2018-10-11
MX2018015933A (es) 2021-11-16
KR20140117662A (ko) 2014-10-07
CA2963138C (en) 2019-05-14
CN101687912B (zh) 2014-01-22
US20190183993A1 (en) 2019-06-20
IL245478A0 (en) 2016-06-30
US11844826B2 (en) 2023-12-19
KR101722305B1 (ko) 2017-03-31
IL267186B (en) 2020-01-30
US20110182921A1 (en) 2011-07-28
WO2008094538A3 (en) 2009-02-26
US20180289782A1 (en) 2018-10-11
US10213496B2 (en) 2019-02-26
AU2008211227A1 (en) 2008-08-07
JP2010516290A (ja) 2010-05-20
ATE525392T1 (de) 2011-10-15
EP2125883B9 (en) 2014-04-23
JP2024059975A (ja) 2024-05-01
US20210252119A1 (en) 2021-08-19
JP4866467B2 (ja) 2012-02-01
US20090018067A1 (en) 2009-01-15
EP2450372B1 (en) 2015-04-22
US20160000892A1 (en) 2016-01-07
US10925941B2 (en) 2021-02-23
JP2022177270A (ja) 2022-11-30
JP6472476B2 (ja) 2019-02-20
EP2423221A1 (en) 2012-02-29
AU2008211227B2 (en) 2014-04-17
US20220211827A1 (en) 2022-07-07
EP2125883A2 (en) 2009-12-02
EP2450370A1 (en) 2012-05-09
US10925940B2 (en) 2021-02-23
US11045530B2 (en) 2021-06-29
CA3161849A1 (en) 2008-08-07
EP2423219B1 (en) 2015-04-29
CN101687912A (zh) 2010-03-31
EP2896630B1 (en) 2020-12-23
EP2423222B1 (en) 2015-04-29
KR20100014871A (ko) 2010-02-11
EP2423220A1 (en) 2012-02-29
CN103755789B (zh) 2016-12-07
US20190183994A1 (en) 2019-06-20
CA2677073C (en) 2016-03-15
CA2915168C (en) 2017-05-23
CN107011431B (zh) 2020-11-06
IL267186A (en) 2019-08-29
US7884184B2 (en) 2011-02-08
EP2450372A1 (en) 2012-05-09
EP2450367A1 (en) 2012-05-09
EP2423220B1 (en) 2015-04-29
CA3034396A1 (en) 2008-08-07
CA3034396C (en) 2022-08-02
JP2021107444A (ja) 2021-07-29
US20190351036A1 (en) 2019-11-21
EP2896630A1 (en) 2015-07-22
MX347197B (es) 2017-04-18
US12016909B2 (en) 2024-06-25
EP2450369A1 (en) 2012-05-09
JP2021107443A (ja) 2021-07-29
US20190030143A1 (en) 2019-01-31
US20180289783A1 (en) 2018-10-11
US10980867B2 (en) 2021-04-20
US20180289785A1 (en) 2018-10-11
JP2012087128A (ja) 2012-05-10
US11045532B2 (en) 2021-06-29
EP2450371A1 (en) 2012-05-09
EP2450368A1 (en) 2012-05-09
CA3001783A1 (en) 2008-08-07
JP2019089793A (ja) 2019-06-13
JP6121369B2 (ja) 2017-04-26
US10925939B2 (en) 2021-02-23
EP2423219A1 (en) 2012-02-29
EP2450366A1 (en) 2012-05-09
JP2014240404A (ja) 2014-12-25
EP2450371B1 (en) 2015-04-29
US10925942B2 (en) 2021-02-23
WO2008094538A2 (en) 2008-08-07
US20180289784A1 (en) 2018-10-11
CA2915168A1 (en) 2008-08-07
US20180289786A1 (en) 2018-10-11
US11045531B2 (en) 2021-06-29
US20180289788A1 (en) 2018-10-11
CA2677073A1 (en) 2008-08-07
US11045528B2 (en) 2021-06-29
CA2963138A1 (en) 2008-08-07
CN103755789A (zh) 2014-04-30
EP2125883B1 (en) 2011-09-21
US20210236609A1 (en) 2021-08-05
US10751397B2 (en) 2020-08-25
JP5643739B2 (ja) 2014-12-17
IL200129A (en) 2016-10-31
EP2423222B9 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
MX2009008230A (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
PH12015501848A1 (en) Binding agents
UA111818C2 (uk) Антитіло проти csf-1r
MY174493A (en) Binding agents
MY156315A (en) Anti-vegf antibodies
IL244803B (en) Human anti-beta antibodies and their use
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ621170A (en) Anti-human cd52 immunoglobulins
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
TR200807263A2 (tr) IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
NZ607615A (en) Antibodies directed against il-17
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2005076972A3 (en) Chimeric vegf peptides
WO2010063833A3 (en) Plant growth promoting protein complex
PH12021553121A1 (en) Novel cthrc1-specific antibody and use thereof
WO2010127180A3 (en) Dc-stamp antibodies
WO2011161545A3 (en) Non-hydrolyzable protein conjugates, methods and compositions related thereto
UA100692C2 (ru) Днк-плазмиды, имеющие повышенную экспрессию и стабильность
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
AU2012261508A1 (en) Wise binding antibodies and epitopes

Legal Events

Date Code Title Description
FG Grant or registration